Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.42 |
| ▸ | ITK | Q08881 | 9/20 | 0.42 |
| ▸ | BTK | Q06187 | 6/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980771 | 1.00 | EGFR (0.42) | EGFRITKBTKJAK3 | |
| SCHEMBL30931295 | 0.93 | BTK (0.44) | EGFRITKBTKJAK3 | |
| SCHEMBL27240906 | 0.93 | BTK (0.44) | EGFRITKBTKJAK3 | |
| SCHEMBL27240869 | 0.90 | JAK3 (0.45) | EGFRBTKJAK3 | |
| SCHEMBL27240850 | 0.90 | JAK2 (0.42) | EGFRITKBTKJAK3 | |
| SCHEMBL27240866 | 0.88 | EGFR (0.45) | EGFRITKBTKJAK3 | |
| SCHEMBL30931265 | 0.88 | EGFR (0.45) | EGFRITKBTKJAK3 | |
| SCHEMBL27240820 | 0.87 | EGFR (0.42) | EGFRITKBTKJAK3 | |
| SCHEMBL27240878 | 0.87 | LRRK2 (0.46) | EGFRITKBTKJAK3 | |
| SCHEMBL29929286 | 0.87 | JAK3 (0.52) | EGFRITKBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| EP-4297873-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | Tyra Biosciences, Inc. (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182972-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | TYRA BIOSCIENCES, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240190849-A1 | AMINOPYRIMIDINE COMPOUNDS AND METHODS OF THEIR USE | DPYD, TYMP, TYMS | EGFR 1313/4885ITK 2477/4885BTK 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.